How will the pharma contract manufacturing market perform from 2011? Our new report shows you potential revenues and trends to 2021, discussing opportunities and prospects.

Discover the activities shaping the outsourcing of pharma manufacturing. Through our research and analysis we aim to save you time and help in your decisions.

How will changes in pharma affect production outsourcing and contract service providers? Which submarket and countries will give the highest revenues from 2011? Our study explains.

You can find potential revenues for pharma manufacturing services at total world, submarket and national levels to 2021. Assess prospects for contract manufacturers and their clients.

See revenue predictions and discussions for active pharmaceutical ingredient (API) and finished dosage form manufacturing. Discover opportunities in biologics and small-molecule drugs. Find data you need in our report.

Assess companies such as Catalent, Lonza, Patheon, Divis Laboratories, Royal DSM, Boehringer Ingelheim and Piramal Healthcare. Outsourcing of pharma manufacturing will become more important this decade.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Analysis with revenues, future growth rates, market shares, opinions and discussions
In our report you find revenue forecasts, growth rates and market shares. You also receive qualitative analyses, opinions from our survey and a review of companies. Discover 85 tables and charts and two research interviews (shown in the accompanying lists).

Pharmaceutical Contract Manufacturing: World Market Outlook 2011-2021 shows you opportunities, challenges and revenue forecasts
Our report gives you the following advantages:

• Discover revenue forecasts to 2021 for the overall world market
• Receive revenue forecasts to 2021 for submarkets, finding growth potential
• Investigate pharma contract manufacturing for a range of technologies and applications
• Assess leading companies in production outsourcing, finding activities and outlooks
• Discover revenue forecasts to 2021 for the US, Japan, Germany, France, Italy, the UK, Spain, India and China
• Assess competition and opportunities that will influence revenues
• Find out what will stimulate and restrain the industry and market from 2011
• View opinions from authorities on pharma outsourcing, seeing different perspectives.

There, you find a distinctive mix of quantitative and qualitative analysis with independent predictions. We tackle crucial questions in pharma manufacturing, helping you to stay ahead.

Order our report now to gain industry and market analysis for contract manufacturing
Our report is for everybody needing industry and market analysis for pharma contract manufacturing. Find trends and answers. Avoid missing out – please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Table of Contents

1. Executive Summary
   1.1 Pharmaceutical Contract Manufacturing: Market Review
   1.2 Chapter Breakdown
   1.3 Research and Analysis Methods

2. Introduction to Pharmaceutical Contract Manufacturing
   2.1 Pharmaceutical Outsourcing
      2.1.1 Contract Research Organisations (CROs)
      2.1.2 Contract Manufacturing Organisations (CMOs)
      2.1.2.1 Contract Development and Manufacturing Organisations (CDMOs)
   2.2 Reasons for Outsourcing Manufacturing
      2.2.1 Tactical Outsourcing
         2.2.1.1 A Lack of Capacity
      2.2.2 Strategic Outsourcing
         2.2.2.1 Big Pharma Focusing on Core Competencies
      2.2.3 The Rise of Generics
      2.2.4 The Rise of Biotechnology
      2.2.5 Virtual Companies

   3.1 The Pharmaceutical Contract Manufacturing Market in 2010
      3.1.1 Recent Trends in the Contract Manufacturing Industry and Market
   3.2 Pharmaceutical Contract Manufacturing Market Forecast 2011-2021
   3.3 Contract API Manufacturing
      3.3.1 API Manufacturing Market 2010
      3.3.2 API Manufacturing Market Forecast 2011-2021
      3.3.3 Highly Potent APIs (HPAPIs)
      3.3.3.1 SAFC: Specialising in HPAPIs
   3.4 Contract Finished Dosage Form Manufacturing
3.4.1 Finished Dosage Form Market in 2010
3.4.2 Finished Dosage Form Market Forecast 2011-2021
3.4.3 Injectables

4. Leading Contract Manufacturing Organisations in 2011
4.1 A Highly Fragmented Market
4.2 Catalent
4.2.1 Revenues and Recent Performance Analysis
4.2.2 Expanded Oral Delivery Technologies
4.3 Lonza
4.3.1 Revenue and Recent Performance Analysis
4.3.2 Lonza Leveraging its Biologics Expertise
4.3.2.1 Teva and Lonza’s Biosimilars Joint Venture
4.4 Royal DSM (DSM)
4.4.1 Revenue and Recent Performance Analysis
4.4.2 Future Outlook
4.5 Boehringer Ingelheim
4.5.1 Revenue and Recent Performance Analysis
4.5.2 Boehringer Acquires Amgen’s Biopharmaceutical Facility
4.5.3 Boehringer Partners with Pfenex
4.6 Patheon
4.6.1 Revenue and Recent Performance Analysis
4.6.2 Expanded Services
4.7 Famar
4.7.1 New Facilities in Spain Expanding Famar’s Reach
4.8 Fareva
4.9 Haupt Pharma
4.9.1 Haupt Pharma Increases its Capacity
4.10 Aenova
4.11 Recipharm
4.11.1 Revenue and Recent Performance Analysis
4.11.2 Recipharm’s 2010 Acquisitions
4.11.3 Future Growth
4.12 Divis Laboratories
4.12.1 Revenue and Recent Performance Analysis
4.13 Jubilant Life Sciences
4.13.1 Revenue and Recent Performance Analysis
4.14 Piramal Healthcare
4.14.1 Revenue and Recent Performance Analysis
4.14.2 Piramal Seeking to Expand
4.15 Evonik Degussa
4.16 Kemwell
4.16.1 Facility and Service Expansion

5.1 The Decision to Outsource Manufacturing
5.2 Risks in Contract Manufacturing
5.3 Technology Transfer
5.4 Globalisation
5.4.1 The Appeal of Asia
5.5 CMO Proximity
5.6 Surviving in an Increasingly Competitive Market
5.6.1 CMO Consolidation
5.6.2 Strategic Partnering
5.6.3 Buying-Out Pharma’s Facilities
5.6.3.1 There Are Risks in Buying-Out Pharma’s Facilities
5.6.4 The Risk of Overcapacity
5.6.5 CMO Specialisation as a Way to Compete
5.6.5.1 Lyophilisation
5.6.5.2 Highly Potent APIs and Complex Molecules
5.7 Quality by Design (QbD) and Process Analytical Technology
5.8 CMOs and Biologics
5.8.1 Biosimilars Offer New Opportunities
5.8.2 Therapeutic Peptides Remain a Strong Market Opportunity
5.9 Virtual Companies
5.10 Outsourcing to Emerging Markets

6.1 Good Manufacturing Practice (GMP)
6.1.1 Harmonisation of Global Requirements
6.1.1.1 US, Australian and EU Collaboration
6.2 US Manufacturing Regulations
6.2.1 Recent and Future Developments
6.2.1.1 Foreign API Manufacture
6.3 European Manufacturing Regulations
6.3.1 The Qualified Person
6.3.2 APIs in the EU
6.3.3 Changes to EU GMP Regulations
6.4 GMP in Japan
6.5 Manufacturing Regulations in India
6.6 China: New GMP Regulations for 2011

7.1 Breakdown of the World Pharmaceutical Market 2010
7.2 The US Market
7.3 The European Market
7.3.1 Germany and France
7.3.2 Italy
7.3.3 Spain
7.3.4 The UK
7.3.4.1 SCM Pharma: An Example of Specialisation
7.4 The Japanese Market
7.4.1 CMIC CMO: a Leading Japanese CMO
7.5 The Indian Market
7.5.1 India as an Outsourcing Destination
7.5.1.1 Indian Intellectual Property
7.6 The Chinese Market
7.6.1 China as an Outsourcing Destination
7.7 Chapter Summary

8. Opinions from Our Survey of the Industry
8.1 Alex Mello, Director of Project Management, Microtest Laboratories
8.1.1 Microtest Laboratories
8.1.2 Technological Developments to Benefit CMOs
8.1.3 Opportunities in the US Contract Manufacturing Market
8.1.4 Restraints in the US Contract Manufacturing Market
8.1.5 Clinical Trial Material Manufacture
8.1.6 CMOs Expanding Their Services
8.2 Hervé Bichon, Vice President, Pharma Sales, Fareva
8.2.1 Technological Developments to Benefit CMOs
8.2.2 Commercial Restraints and Opportunities in the European Pharmaceutical Contract Manufacturing Market
8.2.3 The Role of the Full-Service CMO
8.2.4 South America as an Opportunity

9. Conclusions
9.1 Market Growth 2011-2021
9.1.1 Demand for Contract Manufacturing Will Increase Worldwide
9.1.2 Trend in Outsourcing to Asia Will Continue
9.2 Market Consolidation
9.3 The Rise of Biologics and Biosimilars

List of Tables
Table 1.1 Currency Exchange Rates, 2010
Table 2.1 Leading Biological Drugs by Revenue, 2010
Table 3.1 Pharmaceutical Contract Manufacturing Market, 2010
Table 3.2 Pharmaceutical Outsourcing Market, 2010
Table 3.3 Leading Developed Market Companies Revenue Growth, 2009-2010
Table 3.4 Pharmaceutical Contract Manufacturing: Market Forecasts for Total Market, APIs and Finished Dosage Form, 2010-2021
Table 3.5 Pharmaceutical Contract Manufacturing: Market Drivers and Restraints, 2011-2021
Table 3.6 API Contract Manufacturing: Market Drivers and Restraints, 2011-2021
Table 3.7 Finished Dosage Form Contract Manufacturing: Market Drivers and Restraints, 2011-2021
Table 4.1 Catalent Revenue by Sector, 2010
Table 4.2 Catalent Contract Manufacturing Revenue, 2010
Table 4.3 Catalent Contract Manufacturing Revenue, Q1-Q3 2011
Table 4.4 Lonza Revenue, 2010
Table 4.5 DSM Pharmaceutical Products Revenue, 2009-2010
Table 4.6 Boehringer Ingelheim Revenue, 2009-2010
Table 4.7 Patheon Revenue by Sector, 2009-2010
Table 4.8 Patheon Contract Manufacturing Revenue by Region, 2009-2010
Table 4.9 Recipharm Revenue by Sector and Region, 2010
Table 4.10 Divis Laboratories Revenue, 2010-2011
Table 4.11 Divis Laboratories Revenue by Region, 2010
Table 4.12 Jubilant Life Sciences Revenue by Sector, 2010-2011
Table 4.13 Jubilant Life Sciences Pharmaceutical and Life Sciences Revenue, 2010
Table 4.14 Jubilant Life Sciences CRAMS Revenue, 2010
Table 5.1 SWOT Analysis for the Pharmaceutical Contract Manufacturing Market, 2011-2021
Table 5.2 BRIC Sites for Leading CMOs and CROs, 2011
Table 5.3 BRIC Sites for Leading CMOs and CROs by Country, 2011
Table 5.4 Selected Manufacturing Site Buyouts, 2009-2011
Table 5.5 Selected CMOs Specialising in Lyophilisation, 2011
Table 5.6 Lyophilisation Services: Market Forecast, 2010-2021
Table 5.7 Biological Drugs: Market Forecast, 2010-2021
Table 5.8 India and China: Contract Manufacturing SWOT Chart, 2011-2021
Table 5.9 Top US DMF Holders in India and China, 2007-2008
Table 6.1 FDA Foreign Manufacturing Site Inspections, 2007-2009
Table 7.1 Pharmaceutical Contract Manufacturing Market by Region, 2010
Table 7.2 Pharmaceutical Contract Manufacturing: Market Forecasts by Region, 2010-2021
Table 7.3 European Pharmaceutical Contract Manufacturing Market, 2010
Table 7.4 EU Membership Status of CEE Countries, 2011
Table 7.5 European Pharmaceutical Contract Manufacturing: Market Forecasts for Leading Countries, 2010-2021
Table 7.6 CMIC CMO Revenue, 2009-2011

List of Figures
Figure 2.1 Outsourcing the Pharmaceutical Product Lifecycle
Figure 2.2 Expanding Roles of CROs and CMOs, 2011
Figure 2.3 Leading Biological Drugs by Revenue, 2010
Figure 3.1 Pharmaceutical Contract Manufacturing World Market, 2010
Figure 3.2 Pharmaceutical Outsourcing Market, 2010
Figure 3.3 Leading Developed-Market Companies: Revenue Growth, 2009-2010
Figure 3.4 Pharmaceutical Contract Manufacturing: Market Forecasts, 2010-2021
Figure 3.5 API Contract Manufacturing: Market Forecast, 2010-2021
Figure 3.6 Finished Dosage Form Contract Manufacturing: Market Forecast, 2010-2021
Figure 4.1 Catalent Revenue by Sector, 2010
Figure 4.2 Catalent Contract Manufacturing Revenue, 2010
Figure 4.3 Catalent Contract Manufacturing Revenue, Q1-Q3 2011
Figure 4.4 Lonza Revenue, 2010
Figure 4.5 DSM Pharmaceutical Products Revenue, 2009-2010
Figure 4.6 Boehringer Ingelheim Revenue, 2009-2010
Figure 4.7 Patheon Revenue by Sector, 2009-2010
Figure 4.8 Patheon Contract Manufacturing Revenue by Region, 2010
Figure 4.9 Recipharm Revenue by Sector and Region, 2010
Figure 4.10 Divis Laboratories Revenue, 2010-2011
Figure 4.11 Divis Laboratories Revenue by Region, 2010
Figure 4.12 Jubilant Life Sciences CRAMS Revenue, 2010
Figure 5.1 Cost-Benefit Analysis for Strategic Outsourcing
Figure 5.2 BRIC Sites for Leading CMOs and CROs by Country, 2011
Figure 5.3 Lyophilisation Services: Market Forecast, 2010-2021
Figure 5.4 Biological Drugs: Market Forecast, 2010-2021
Figure 6.1 ICH Manufacturing Guidelines: Developed Market Adoption, 2000-2010
Figure 6.2 FDA Foreign Manufacturing Site Inspections, 2009
Figure 7.1 Pharmaceutical Contract Manufacturing Market by Region, 2010
Figure 7.2 US Contract Manufacturing: Market Forecast, 2010-2021
Figure 7.3 European Pharmaceutical Contract Manufacturing Market, 2010
Figure 7.4 European Pharmaceutical Contract Manufacturing: Market Forecast, 2010-2021
Figure 7.5 French and German Pharmaceutical Contract Manufacturing: Market Forecasts, 2010-2021
Figure 7.6 Italian Pharmaceutical Contract Manufacturing: Market Forecast, 2010-2021
Figure 7.7 Spanish Pharmaceutical Contract Manufacturing: Market Forecast, 2010-2021
Figure 7.8 UK Pharmaceutical Contract Manufacturing: Market Forecast, 2010-2021
Figure 7.9 Japanese Pharmaceutical Contract Manufacturing: Market Forecast, 2010-2021
Figure 7.10 CMIC CMO Revenue, 2009-2011
Figure 7.11 Indian Pharmaceutical Contract Manufacturing: Market Forecast, 2010-2021
Figure 7.12 Indian Intellectual Property Law 1970-2011
Figure 7.13 Chinese Pharmaceutical Contract Manufacturing: Market Forecast, 2010-2021
Figure 7.14 Pharmaceutical Contract Manufacturing Market by Region, 2016
Figure 7.15 Pharmaceutical Contract Manufacturing Market by Region, 2021
Figure 9.1 Pharmaceutical Contract Manufacturing: Market Forecasts, 2010, 2016 and 2021
Figure 9.2 Pharmaceutical Contract Manufacturing: Market Forecasts by Region, 2010, 2016 and 2021

Companies Listed

Abbott Laboratories
Aenova (formerly Dragenopharm Apotheke Püschl and Swiss Caps)
Akrimax Pharmaceuticals
AlgoNomics (now part of Lonza)
Amgen
AstraZeneca
Australian Therapeutic Goods Administration (TGA)
Avesthagen
Bayer
BIOLYPH
Biopharma Technology
Boehringer Ingelheim
Bridgepoint
Cardinal Health
Catalent
Centocor (a subsidiary of J&J)
Charles River Laboratories
Chongqing Carelife Pharmaceutical
Chongqing Daxin Pharmaceutical
CMIC CMO
CMIC CMO Korea
CMIC CMO Toyama
CMIC CMO USA
CMIC Group
Cobra Biomanufacturing (now RecipharmCobra Biologics)
Covance
Daiichi Sankyo
Department of Pharmaceuticals [India]
Divis Laboratories
Eli Lilly
European Fine Chemicals Group (EFCG)
European Medicines Agency (EMA)
Evonik Degussa
Famar
Fareva
FDA Office of Combination Products (OCP) [US]
Food and Drug Administration (FDA) [US]
Gallus BioPharmaceuticals
GlaxoSmithKline (GSK)
Haupt Pharma
Haupt Pharma Amareg
Hetero Drugs
Hollister (now Jubilant HollisterStier Contract Manufacturing and Services)
 Hospira
Human Genome Sciences
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
Janssen-Cilag (subsidiary of J&J)
Johnson & Johnson (J&J)
Jubilant Life Sciences (formerly Jubilant Organosys)
Kemwell
Lonza
Lupin Pharmaceuticals
Lyka Labs
Lyofal
Lyophilization Services of New England
Lyophilization Technology
Marinopoulos Group
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Merck & Co.
Microtest Laboratories
Millennium Pharmaceuticals
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
NKT Therapeutics
Novartis
Orchid Chemicals and Pharmaceuticals
Oregon Freeze Dry
Orexigen Therapeutics
Oxford BioMedica
Pantec
Parexel
Patheon
Pfénex
Pfizer
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
Polymed Therapeutics
PPD
PRWT Services
Quintiles
Recipharm
Recipharm Parets
Ridgemont Equity Partners
Roche
rommelag
Royal DSM
SAFC
SafeBridge Consultants
Samsung
Sanofi
Schering-Plough (now part of Merck & Co.)
SCM Pharma (formerly Specials Clinical Manufacturing)
Shandong New Time Pharmaceutical
Sinochem Group
Society of Chemical Manufacturers and Affiliates (SOCMA) [US]
Solvay Pharmaceuticals (now part of Abbott Laboratories)
Specialty European Pharma
State Food and Drug Administration (SFDA) [China]
Sun Pharmaceutical Industries
Takeda Pharmaceutical Company
Teva Pharmaceutical Industries
The Blackstone Group
The Specials Laboratory
TraceLink
US Government Accountability Office (GAO)
Vivante GMP Solutions (now part of Lonza)
Wasserburger Arzneimittelwerk (now part of Recipharm)
Wockhardt
World Health Organization (WHO)
World Trade Organization (WTO)
Wyeth (now part of Pfizer)
Zhejiang Jiuzhou Pharmaceutical

2011 Copyright © visiongain. All rights reserved. BSG House, 226-236 City Road, London, EC1V 2QY, United Kingdom